About Abraxis bioscience
Abraxis Bioscience: Revolutionizing Healthcare with Innovative Medicines
Abraxis Bioscience is a leading biopharmaceutical company that is dedicated to discovering, developing, and delivering innovative medicines to patients suffering from serious diseases. The company has been at the forefront of medical research for over two decades and has made significant contributions to the field of oncology.
Founded in 1999, Abraxis Bioscience was acquired by Bristol Myers Squibb in 2010. Since then, the company has continued its mission of improving patient outcomes through cutting-edge research and development. With a team of highly skilled scientists and researchers, Abraxis Bioscience is committed to advancing the science of medicine and finding new ways to treat some of the most challenging diseases facing humanity today.
At Abraxis Bioscience, we believe that every patient deserves access to safe and effective treatments that can improve their quality of life. That's why we are constantly pushing the boundaries of medical science with our innovative drug development programs. Our focus on oncology has led us to develop several groundbreaking therapies that have helped thousands of cancer patients around the world.
One such therapy is Abraxane®, a protein-bound chemotherapy agent used in combination with other drugs for treating breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors. This revolutionary drug delivery system allows for higher doses of chemotherapy drugs while minimizing side effects such as hair loss and nausea.
Another breakthrough therapy developed by Abraxis Bioscience is nab®-paclitaxel (Abraxane®), which uses albumin nanoparticles as a delivery vehicle for paclitaxel – an anti-cancer drug used in chemotherapy treatment. This innovative approach improves efficacy while reducing toxicity compared with traditional paclitaxel formulations.
In addition to our work in oncology, we are also actively researching treatments for other serious diseases such as HIV/AIDS, hepatitis C virus (HCV), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD) among others.
At Abraxis Bioscience we understand that innovation alone isn't enough; it must be coupled with responsible business practices aimed at ensuring access to affordable healthcare solutions worldwide. We strive towards this goal by partnering with governments across different countries where our products are available so as ensure affordability without compromising on quality or safety standards.
Our commitment towards sustainability extends beyond just providing affordable healthcare solutions but also includes environmental stewardship through sustainable manufacturing processes aimed at reducing carbon footprint while maintaining high-quality standards throughout all stages from R&D through commercialization.
In conclusion,
Abraxis biosciences' dedication towards discovering new ways to treat some challenging diseases facing humanity today makes them one-of-a-kind biopharmaceutical companies globally.
Their focus on oncology has led them into developing several groundbreaking therapies like nab-paclitaxel(Abraxane) which uses albumin nanoparticles as a delivery vehicle for paclitaxel – an anti-cancer drug used in chemotherapy treatment.
Their commitment towards sustainability extends beyond just providing affordable healthcare solutions but also includes environmental stewardship through sustainable manufacturing processes aimed at reducing carbon footprint while maintaining high-quality standards throughout all stages from R&D through commercialization.
With their cutting-edge research & development programs coupled with responsible business practices aimed at ensuring access to affordable healthcare solutions worldwide makes them stand out amongst their peers globally!